Research has indicated that FlexNow(R) Joint Formula shows significant reductions in cartilage deterioration, joint inflammation, and joint pain.
EGG HARBOR TWP., N.J., Nov. 14 /PRNewswire/ -- BSP Pharma Inc., the maker and distributor of FlexNow(R) Joint Formula, has announced the findings from the new joint health clinical study completed this past June at the Australian Centre for Complementary Medicine Education and Research (ACCMER) in Brisbane, Australia led by Dr. Phillip Cheras PhD.
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/flexnow/29883/
Results show that, for those with elevated cartilage deterioration in their joints, FlexNow Joint Formula provides an unprecedented reduction in cartilage deterioration for a natural product, 44% higher than that reported for glucosamine.(1) This is the first human clinical study of a natural product showing such a great reduction in a well recognised marker for cartilage deterioration as well as significant reductions in joint specific inflammation and joint pain.
FlexNow is an all natural dietary supplement made with one ingredient, an extract from the shea nut which contains one of the most powerful inflammation fighters of any known plant. The ability of shea extract to reduce inflammation in the human body has only recently been discovered.
Dr. Cheras' was asked to be the principal investigator due to his ground breaking research showing it is highly likely that most joint problems are a vascular condition. Prior to this study, research had indicated that FlexNow had a strong ability to address this cause, and not just the symptoms of joint health.
"FlexNow shows great promise and BSP's approach to bringing this product to market is a model for responsible development for complementary medicine," said Cheras.
The research was designed to bring together a large number of previous studies, to confirm the efficacy of shea extract in humans and to further demonstrate the safety of FlexNow. FlexNow is one of only 7 dietary supplements to be accepted by the FDA in 2004 as meeting all safety requirements, which was further shown during the clinical study when there was no difference in adverse effects between FlexNow and placebo.
The biggest clinical surprise was the unprecedented reduction in the breakdown of cartilage, both compared to placebo and for that reported for glucosamine. The other remarkable findings were the strong reduction in inflammatory markers that are produced more in unhealthy joints and joint cartilage than normal joints, and high sensitivity C-reactive protein (hsCRP), which has been found to be higher in patients with unhealthy joints than controls.
"This clinical confirmation that FlexNow is significantly reducing cartilage breakdown and inflammation, gives us insight into why so many FlexNow Joint Formula users are telling us of their joint relief for the first time," said Leonard P. Smith, CEO and President, BSP Pharma Inc., "which is allowing so many people with joint pain to once again lead an active life."
The clinical study is being submitted for publication. Prior clinical studies can be found by visiting http://www.flexnow.us
(1) Christgau S, Henrotin Y, Tanko LB, et al. Osteoarthritic patients with
high cartilage turnover show increased responsiveness to the cartilage
protecting effects of glucosamine sulphate. Clin Exp Rheumatol 2004;
|SOURCE BSP Pharma Inc.|
Copyright©2007 PR Newswire.
All rights reserved